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1. RESUMO 
Introdução: O cancro da próstata é um dos principais responsáveis pela elevada carga 
associada ao cancro, em todo o mundo. O uso generalizado do antigénio específico da 
próstata (PSA), como ferramenta de rastreio, pode ajudar a explicar o aumento observado 
nas taxas de incidência de cancro da próstata, mas o seu papel na diminuição das taxas de 
mortalidade continua controverso. O diagnóstico definitivo de cancro depende da 
confirmação histopatológica após biópsia, pelo que, antes de referir um doente para a 
realização deste procedimento invasivo, o médico deverá ter em conta os valores séricos de 
PSA, de acordo com a idade do doente, o seu índice de massa corporal e a medicação 
habitualmente usada, nomeadamente, estatinas. As estatinas são os agentes 
antidislipidémicos mais prescritos em todo o mundo e apresentam, para além das 
propriedades antidislipidémicas, propriedades anti-inflamatórias, anti-invasivas, inibidoras do 
crescimento tumoral e da angiogénese, potencialmente reduzindo o risco de cancro da 
próstata. As estatinas também podem contribuir para um decréscimo nos níveis de PSA, 
através da diminuição dos níveis de colesterol – uma vez que este é um percursor 
necessário para a síntese de PSA – bem como através da ação sobre o tecido prostático 
benigno. O impacto das estatinas nos níveis de PSA poderá levar a uma diminuição e um 
atraso na deteção de cancro quando se usam os valores de referência habituais, pelo que 
poderá ser necessário ajustar esses valores de referência, de maneira a maximizar a 
sensibilidade e a especificidade do PSA entre utilizadores de estatinas. 
Objetivos: Quantificar o efeito das estatinas nos valores de PSA em doentes referidos para 
biópsia prostática e determinar se o uso de estatinas deve ser tido em conta para melhorar a 
precisão do PSA, enquanto ferramenta de diagnóstico de cancro da próstata. 
Métodos: Foram selecionados 551 doentes com PSA ≤ 10,0ng/mL, referidos para biópsia 
prostática por apresentarem PSA ≥ 2,5ng/mL ou um achado anormal no exame de toque 
retal. Os resultados patológicos foram definidos pela biópsia e as informações relativamente 
ao uso de estatinas foram recolhidas dos registos clínicos dos doentes. Usámos a 
ferramenta matemática “path analysis” para quantificar o efeito das estatinas no PSA, tendo 
em conta variáveis escolhidas de entre aquelas que se associam a uma relação causal entre 
as estatinas e o PSA. Também usámos Receiver Operating Characteristic curves para 
avaliar a precisão de modelos, que incluíam como variáveis: os valores de PSA, a idade, o 
índice de massa corporal, o uso de inibidores da 5-α-reductase, o uso de aspirina e 
estatinas, para distinguir entre cancro da próstata ou situações benignas. 
Resultados: Observou-se um efeito total das estatinas sobre os níveis de PSA (β=-0.283; 
IC 95%:-0.618, 0.051), principalmente devido ao efeito direto (estatinas→PSA) (β=-0,243; IC 
95 %:-0.587,0.101), em vez do efeito indireto (estatinas→cancro→PSA) (β=-0.040; IC 95%:-
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0.178, 0.097). Não houve diferenças estatisticamente significativas entre as áreas sob a 
curva correspondentes aos modelos com ou sem estatinas (P=0,554). Este estudo é limitado 
pela sua natureza transversal, pela falta de informação sobre a duração do tratamento com 
estatinas, e também pelo facto de os resultados não poderem ser extrapolados para 
populações um risco diferente de cancro da próstata. 
Conclusão: Numa amostra consecutiva de pacientes referidos para biópsia prostática, o 
uso habitual de estatinas foi associado a níveis mais baixos de PSA, principalmente devido 
a uma ação direta sobre a síntese e metabolismo do PSA, embora com pouco impacto 
sobre o valor preditivo do teste de PSA nesta população específica. 
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2. ABSTRACT 
Background: Prostate cancer is one of the major contributors to the high burden of cancer 
worldwide. The widespread of Prostate Specific Antigen (PSA) as a screening tool might 
explain the increase observed in incidence rates but the role of PSA in the mortality decrease 
is a matter of discussion. The diagnosis of prostate cancer relies on the histopathologic 
confirmation of cancer after biopsy, but to refer for undergoing this procedure, physicians 
must take into account serum PSA levels, according to patients’ age, body mass index and 
medication used, namely statins. Statins are the most prescribed anti-dyslipidemic drugs 
worldwide and present anti-inflammatory, anti-invasive, tumour growth suppressing, 
apoptotic and angiogenesis inhibiting properties – in addition to the lipid lowering effects – 
potentially decreasing the risk of prostate cancer. Statins also contribute to a reduction in 
total PSA levels, reflecting the lowering of cholesterol levels – a precursor in the synthesis of 
PSA, as well as due to their action on benign prostatic tissue. The impact of statins on serum 
PSA levels may lead to a decrease and a delay in prostate cancer detection when using the 
traditional cut-offs for reference to biopsy, and adjustment of the PSA threshold to maximize 
sensitivity and specificity may be needed among statins’ users. 
Objectives: To quantify the effect of statins’ use on Prostate Specific Antigen levels in 
patients referred to prostate biopsy and to determinate if the exposure to statins must be 
considered to improve the prostate cancer diagnostic accuracy of PSA as screening tool. 
Methods: We selected 551 patients with PSA ≤10.0 ng/mL referred to ultrasound guided 
trans-rectal prostate biopsy due to PSA ≥2.5 ng/mL or abnormal digital rectal examination. 
Results of the prostatic pathology assessment (cancer versus non-cancer) were defined by 
biopsy and information regarding statins’ use was obtained from patients’ clinical records. 
We used path analysis to quantify the effect of statins’ use on PSA, taking into account 
variables chosen to assume a causal relation between statins and PSA levels and the 
potential confounders. We also used Receiver Operating Characteristic curves to assess the 
global predictive accuracy of models including PSA, age, body mass index, 5-α-reductase 
inhibitors, aspirin and statins’ use for distinguishing between prostate cancer and benign 
conditions. 
Results: We observed a negative total effect of statins on PSA levels (β=-0.283; 95% CI: -
0.618, 0.051), mostly due to the direct effect (statins →PSA) (β=-0.243; 95% CI: -0.587, 
0.101) rather than the indirect effect (statins→cancer→PSA) (β=-0.040; 95%CI: -0.178, 
0.097). There were no statistically significant differences between the area under the curve 
corresponding to the models with or without statins (P=0.554). This study is limited by its 
cross-sectional nature, lack of information on the duration of treatment with statins and also 
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by the fact that results cannot be extrapolated to settings with a different risk of prostate 
cancer. 
Conclusions: In a consecutive sample of patients referred to prostate biopsy, the current 
use of statins was associated with lower PSA levels, mainly due to a direct action on PSA 
synthesis and metabolism, though this had little impact on the predictive value of PSA testing 
in this setting 
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3. INTRODUCTION 
3.1. Trends in prostate cancer incidence, survival and mortality 
 
Worldwide, prostate cancer is the second most frequent cancer and the sixth cause of 
oncological death in men, with 899 000 incident cases and 258 000 deaths estimated to have 
occurred in 2008 (1). There are major differences across countries regarding prostate cancer 
incidence, with the highest rates observed in the most developed settings and the lowest in 
some countries from South-Central Asia (1). 
Recent analyses of incidence trends show that the rates increased steeply since the 
late 1980s and stabilized in recent years in developed countries (2-4). The upward trends are 
mainly due to the introduction and widespread of Prostate Specific Antigen (PSA) testing as 
a screening tool, and resulted in an increase in the diagnosis of localized cancers and a 
decrease in the diagnosis of severe, metastatic disease (2-4). 
Associated with the use of PSA testing there was an increase in overdiagnosis and in 
adverse outcomes such as erectile dysfunction and urinary incontinence which contributes to 
the high morbidity associated with the diagnosis of prostate cancer (5, 6). To measure the 
burden of this disease, the quantification of disability-adjusted life-years (DALYs) allows for 
the assessment of the degree of illness and disability in patients and long-term survivors (7). 
DALYs are composed by the years of life lost because of premature death (YLLs) and the 
years lived with disability (YLDs) (7). Globally, in 2008, the YLLs were the main contributors 
for the DALYs attributable to cancer; however, the relative contribution varied by region: on 
countries with high human development index (HDI), YLLs were 52% of the DALYs for 
prostate cancer, while in countries with low HDI the contribution from YLLs was 96% (6). 
There was a high contribution from the YLDs due to cancer in the Americas, most European 
countries, Australia and New Zealand and must of the sub-Saharan Africa (6). 
Despite the high burden, prostate cancer presents high survival rates for which the 
early detection and early treatment have contributed (8, 9). In the United States of America 
(USA), the 5-year standardized relative survival was 91.1% among the cases diagnosed 
between 1990-94 and followed-up to 1999, which is the highest in developed countries (8). In 
Europe, the overall prostate cancer 5-year standardized survival was 77% in the period 
1995-1999, with high variability across countries, ranging from 84.9% in Austria and 47.7% in 
Denmark (9).  
Although the effectiveness of PSA testing and radical treatment remain open to 
discussion (10, 11) they are usually indicated as the reasons for the decrease observed in 
mortality rates in several high income countries (12, 13). However, there are some countries, 
13 
 
mainly from Southern and Eastern Europe, that despite the generally low mortality rates, 
show an increase in mortality rates through the last decades (14). 
Regarding treatment, surgery has an arguable efficacy (11) but it has been well 
demonstrated that radiotherapy as a primary treatment improves overall survival (15), 
immediate postoperative radiotherapy improves 5-year biochemical progression-free survival 
(16) and hormone therapy is associated with a longer time to disease progression in 
metastatic disease and longer overall survival when associated with radiotherapy in locally 
advanced disease (17).  
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3.2. Prostate cancer screening and diagnosis 
 
Screening aims to detect disease in asymptomatic people in the earliest stage possible 
and to allow for a more effective treatment, ultimately leading to a decrease in overall and 
disease specific mortality (18). Screening for prostate cancer is performed using serum PSA 
and Digital Rectal Examination (DRE) (19). 
Despite the PSA testing has been widely used for early diagnosis, its use as a 
screening tool at a population level is not supported by the available evidence (18). The most 
recent review of the studies regarding prostate cancer screening (18) identified five relevant 
randomised controlled trials, namely the European randomised study of screening for 
prostate cancer (ERSPC) (20) and the Prostate Lung Colorectal and Ovarian screening trial 
(PLCO) (21), as the ones with low risk of bias, and the Norrkoping (22), the Quebec (23) and 
the Stockholm (24) studies as the ones with more substantive methodological weaknesses 
(18). 
The ERSPC (20) reported a significant 21% relative reduction (95%CI: 31%-8%) in 
prostate cancer-specific mortality in men aged 55-69 years, with the use of PSA screening, 
after 11 years of follow-up (20), while the PLCO study reported no significant effect (Risk 
Ratio (RR) for prostate cancer death=1.15, 95% CI 0.86-1.54) (21). The PLCO’s results are 
criticized due to the low compliance with biopsy in those with elevated PSA levels (31%) and 
due the contamination of the control groups by the performance of PSA testing in patients 
randomized for not being screened, which reflects the community practices in the United 
States; the contamination was estimated to be in the range of 53% and over 40% of men had 
undergone PSA testing before randomization, thus introducing a bias towards not finding a 
benefit of screening (18). In the ERSPC, the contamination rate was lower (≈ 20%) and the 
biopsy compliance was much higher (86%) (18). 
The definitive diagnosis of prostate cancer depends on the histopathologic confirmation 
in prostate biopsy (19, 25).  
In order to correctly refer patients to undergo prostate biopsy and to better assess the 
risk for prostate cancer, several risk calculators have been produced (26). Most of these 
tools consider, besides the PSA levels (27), DRE findings (28) and outcome of prior biopsy 
(26), the well-known risk factors for prostate cancer: age (29), family history (30) and race 
(31). However, the performance of these risk prediction tools depends on the cohort in which 
they were developed and on the PSA cut-off value used to recommend biopsy, since the 
relationship between PSA and risk of a positive prostate biopsy varies between cohorts (26). 
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3.2.1. Prostate Specific Antigen 
 
PSA is a glycoprotein produced by the prostate gland and secreted in prostate lumen 
for liquefying the seminal fluid. In men without prostatic diseases, this protein is limited to 
prostate gland lumen. When any modification occurs in prostate physiology, PSA is released 
to the circulatory system, thus increasing the serum level (27).  
This protein is specific for prostate but it is not specific for prostate cancer and several 
other prostate pathologies can also affect PSA level, including Benign Prostatic Hyperplasia 
(BPH), prostatitis or trauma (32). Although there is unquestionable evidence that prostate 
cancer risk varies with the levels of circulating PSA (27, 33), population-based screening 
programs are not recommended (18). 
Guidelines differ among countries and medical organizations; the United States 
Preventive Services Task Force (USPSTF) recommend against routine widespread 
screening (34) as well as screening in men older than age 75 years, as these men present 
higher risk of adverse effects from treatment and competing causes of mortality making them 
less likely to benefit from screening (26, 34). Other organizations, like the American Cancer 
Society, the American and the European Urological Associations, present some 
recommendations to refer patients to undergo prostate biopsy, based on the presence of 
PSA serum levels above a specified cut-off and/or suspicious DRE (19, 25, 26). Physicians 
must also consider patients’ age, life expectancy, potential co-morbidities and the side 
effects of the prostate biopsy (19, 25).  
The threshold of 4.0ng/mL has been traditionally used for prompting men to undergo 
prostate biopsy (19, 25). PSA testing has an overall sensitivity of 72.1% (66.7% to 100.0%), 
and a specificity of 93.2% (63.1% to 100.0%), when considering a serum PSA level higher 
than 4.0ng/ml, to define an increased risk of prostate cancer (35). The use of lower PSA 
threshold increases sensitivity while decreasing specificity, and no cut-off achieves both high 
sensitivity and high specificity (36). 
To correctly identify the best PSA cut-off value and to increase its sensitivity and 
specificity, it may be necessary to account for some individual factors that affect PSA levels 
namely patients’ age (29), Body Mass Index (BMI) (37) and medications used (38). 
 
Age 
 
The use of age-specific cut-offs takes into account that, in men without prostate cancer, 
serum PSA reflects the amount of glandular epithelium, which in turn reflects prostate size; 
as prostate size increases with age, PSA concentration also rises (39).Therefore, in young 
patients, where almost all prostate cancer cases are clinical relevant and will lead to radical 
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treatment and the health costs of missing a diagnosis of prostate cancer are greater, a higher 
sensitivity is desired; in the older patients, in whom BPH is more likely to cause PSA 
elevation, there is higher probability of overdiagnosis, specificity becomes more relevant (40) 
which explains why, we found higher cut-offs for the older patients (41) (Table 1). 
 
Table 1 – Age-specific reference ranges for serum PSA (42). 
Age range 
(yr.) 
Reference 
range 
(ng/mL) 
40-49 0.0 – 2.5 
50-59 0.0 – 3.5 
60-69 0.0 – 4.5 
70-79 0.0 – 6.5 
 
Body Mass Index 
 
Several studies reported that increased BMI is associated with decreased serum PSA 
levels, due to a hemodilution effect, as a result of greater blood volume or due to 
suppression of PSA production caused by lower testosterone levels and higher oestrogen 
levels among obese men (37, 43). Lower PSA levels in obese men might decrease the 
sensitivity of prostate cancer screening, which would lead to a delayed diagnosis of prostate 
cancer, with an unfavourable prognosis (44, 45). However, the use of BMI-adjusted PSA cut-
offs in prostate cancer screening is controversial and no specific ones have been developed 
(45). 
 
Medication 
 
There is increasing evidence over the impact of several therapeutic groups on PSA 
levels. 
 
5-α-reductase inhibitors 
5-α-reductase inhibitors (5-ARI) are used to treat BPH and have impact on prostate 
cancer due to the inhibition of the conversion of testosterone in dihidrotestosterone, which 
decreases prostatic volume and PSA levels (46-48). 
It is suggested that in 5-ARI users it may be necessary to consider a PSA level that is 
twice the observed for the correct interpretation of the risk of cancer among these subjects 
(49). However, given the considerable inter and intra-individual variability in PSA levels, this 
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adjustment may overestimate actual PSA in some patients receiving 5-ARI for up to 6 to 9 
months, accurately estimate PSA from 1 to 3 years and underestimate it among patients 
treated for more than 3 years (49). Instead, Marks et al recommends that the variation and 
the magnitude of the variation through time should be taken into account in patients under 
treatment with this therapeutic group, rather than a single PSA value (49). They also suggest 
the use of an increase in PSA of 0.3ng/ml or higher from the lowest value achieved with 5-
ARI therapy (PSA nadir) as a trigger for biopsy; this maintains 71% sensitivity for prostate 
cancer in men receiving dutasteride, with 60% specificity, similar to the 4.0 ng/ml PSA cut-off 
using placebo (49).  
 
Non-Steroidal Anti-inflammatory Drugs 
There are reports of PSA levels 10% lower in Non-steroidal anti-inflammatory Drugs 
(NSAIDs) users when compared to non-users (50), and around 9% when comparing 
specifically aspirin with non-aspirin users (51, 52). The differences found might be 
confounded by the fact that men who use physician-prescribed NSAIDs – particularly aspirin, 
since it has preventive action over cardiovascular diseases – are more likely to be frequent 
users of other health services, such as cancer screening activities including PSA testing, 
causing a positive detection bias (52, 53). 
Nevertheless, experimental studies have shown inhibitory effects of Non-steroidal Anti-
inflammatory Drugs (NSAIDs) on prostate cancer cell proliferation and reduction of prostate 
cancer metastasis, suggesting their possible preventive role for prostate cancer (54) and 
NSAIDs also exert their activity on non-carcinogenic tissue, contributing to a reduction in 
serum PSA levels (51). 
 
Thiazide diuretics 
In a study of men over 40 years old without prostate cancer, users of thiazide diuretics 
presented 6% lower PSA levels after one year of therapy when compared to non-users (38). 
The results might be due to the depletion of vitamin D which is needed for the secretion of 
PSA and also due the induction of an androgen deficient state (androgens are needed for 
PSA production) (38). 
 
Statins 
Cholesterol is an essential molecule for the cell physiology; it is one of the main 
constituents of cell membranes, is responsible for the maintenance of membrane structural 
integrity and is also involved in cell signalling processes (55). 
Several studies suggested that men with hypercholesterolemia are at increased risk for 
prostate cancer or late stage, aggressive disease (55-57). Moreover, prostate synthesises 
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cholesterol at a higher rate than the liver and it was found that cholesterol accumulation in 
prostate glandular tissue doubles further as the prostate progresses from benign to 
cancerous states (55). Therefore, perturbations on cholesterol metabolism are likely to 
influence cancer development and progression. 
Statins are the most prescribed lipid lowering drugs within countries of the Organization 
for the Economic Co-operation and Development (OECD), with an estimated average daily 
consumption of 85.3 Defined Daily Dose (DDDs) per 1000 people (58). In  2011, in the USA, 
lipid regulators were responsible for a spent of 20.1$BN, with 19.8 million people treated with 
anti-cholesterol medicines (59). In Portugal, this therapeutic group represented the fourth 
most sold and around 9% of the total National Health Service medicines sales in 2011 (60).  
The updates on the guidelines for cardiovascular disease prevention, with the definition 
of lower cut-offs for cholesterol levels associated with high cardiovascular risk, the 
recommendation for statins use in both primary and secondary prevention of cardiovascular 
events (61) and the intense marketing policies from pharmaceutical companies (62), 
contributed to the increasing use of statins over the last decades (63). 
Statins act by inhibiting the Hydroxy-methyl-glutaryl Co-enzyme A (HMG CoA) 
reductase, responsible for the rate-limiting step in cholesterol synthesis – the conversion of 
hydroxyl-methyl-glutaryl in mevalonate (as depicted in Figure 1) (64). 
 
 Figure 1 – The mevalonate pathway (adapted from Murtola et al (65))  
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The mevalonate pathway, in addition to the cholesterol synthesis, is also responsible 
for the biosynthesis of other metabolites like the isoprenoids geranyl-geranyl-pyrophosphate 
(GGPP) and farnesyl-pyrophosphate (FPP), which are lipid attachments that constitute key 
intermediates for a series of events essential for the activation and intra-cellular transport of 
cell-signalling proteins (64). These proteins act as molecular switches, controlling multiple 
pathways and cell functions such as maintenance of cell shape, motility, factor secretion, 
differentiation and proliferation (64). These effects, known as pleiotropic effects, are 
cholesterol-independent and include improvement of the endothelial function, inhibition of 
vascular inflammation and oxidation and stabilizing of atherosclerotic plaques (64, 66, 67). 
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3.3. Statins and serum PSA 
 
In addition to the lipid lowering properties of statins, these drugs have shown anti-
inflammatory, anti-invasive, tumour growth suppressing (68), apoptotic (69) and 
angiogenesis inhibiting properties (70) potentially decreasing the risk of several cancers (64). 
Epidemiological evidence supports the association between statins therapy and overall 
cancer (71, 72) and reports significant reduced risk of specific cancer subtypes, namely liver 
cancer (RR=0.58, 95% CI: 0.46–0.74) (73), gastric cancer (Odds Ratio (OR)=0.70, 95%CI: 
0.51-0.97) (74), esophageal cancer (OR=0.72; 95% CI: 0.60-0.86) (75) and reduced breast 
cancer recurrence among statins’ users (RR=0.53, 95 % CI: 0.37-0.76) (76). Although it was 
not found an association between statins use and lung cancer, there are currently clinical 
trials testing the association of statins and anti-carcinogenic drugs, once statins might 
enhance the antitumor activity of various cytokines and chemotherapeutic agents specifically 
used in lung cancer treatment (77). 
Dale et al (71), performed a systematic review of Randomized Control Trials (RCTs) of 
statins for cardiovascular prevention available until July 2005 and with information regarding 
cancer incidence and cancer deaths. They concluded that statins did not reduce the 
incidence of cancer (OR)=1.02, 95%CI: 0.97-1.07) or cancer deaths (OR=1.01, 95%CI: 0.93-
1.09) (71). However some limitations were identified: the RCTs used in this study were 
designed to evaluate cardiovascular endpoints and, therefore, the definition of cancer as 
outcome might be limited; there were concerns about the patients’ characteristics of those 
enrolled in the statin RCTs, since that, to maximize the effect of statins, the patients in these 
studies had a very high risk of cardiovascular disease events what represents a competing 
outcome for cancer diagnostic (71). Finally, if statins are chemo protective through their 
antioxidant properties, they may need to be given much earlier in life to be efficacious. It has 
been argued that antioxidants must be taken before significant oxidative damage has 
occurred to prevent cancer; therefore, the statin RCTs conducted might not have thoroughly 
examined the ability of statins to act as cancer chemo preventive drugs (71, 72). 
Taylor et al (72), performed a meta-analysis of case-control studies that examined the 
relationship between any statin and neoplasm at any site. They found that the overall OR 
revealed a protective effect for statins of 0.71 (95%CI: 0.56–0.89) (72). The major 
weaknesses of this meta-analysis lied in the inherent potential biases of case–control 
studies, such as “recall bias” and “misclassification bias”. In addition, there could be other 
confounding factors that caused a false relationship to be identified between statins and all-
cancers (72). 
Prostate cancer is one of the cancer subtypes with evidence supporting a preventive 
role of statins over cancer incidence (78, 79). 
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3.3.1. Indirect effect 
 
In a meta-analysis of both RCTs, with cancer as secondary endpoint, and 
observational studies, Bonovas et al, found a non-significant reduction on the risk of prostate 
cancer with the use of statins (pooled RR estimate: 0.95, 95%CI: 0.73-1.23) (78). However, 
in reports that specifically examined statins’ use and advanced prostate cancer, they found a 
protective association (RR: 0.77, 95%CI: 0.64-0.93) (78). 
Bansal et al (79), updated Bonovas’ meta-analysis and included 17 more studies that 
were published after 2007. They found a significant inverse association between statin use 
and risk of total prostate cancer among cohort studies (RR=0.93, 95% CI: 0.87–1.01, p=0.09) 
and a non-significant inverse association among case-control studies (RR=0.87, 95%CI: 
0.72–1.05, p=0.15) (79). The difference between these results and those presented by 
Bonovas et al. is likely to be due to the inclusion of 8 new studies that showed a negative 
association between statins and risk of total prostate cancer, as it was demonstrated by the 
cumulative meta-analysis performed (79). The reasons for this shift in the association might 
be the change in the behaviour regarding PSA testing, which lead to detection of early stage 
disease. Another explanation might be the fact that cholesterol levels in the pre-PSA era 
have a greater chance of being a product of tumour metabolism, leading to a positive 
association between statins and cancer, whereas cholesterol levels in post-PSA studies are 
more likely to reflect the cholesterol environment prior to the development of cancer (79). 
There are several mechanisms that help explaining the association between statins’ 
use and prostate cancer, as presented in Figure 2, and they involve actions on cell cycle, 
apoptosis, angiogenesis and inflammation (80). 
  
22 
 
Figure 2 – Potentially protective and harmful effects of statins on prostate tumourigenesis 
(Adapted from Papadopoulos et al (80)). 
 
 
 
3.3.2. Direct effect 
 
Statins may also contribute to a reduction in total PSA levels, due to their actions over 
benign prostatic tissue and over cholesterol metabolism – a precursor in the synthesis of 
PSA (80). 
The first study that assessed the impact of statins on PSA values was performed on a 
small cohort of airline pilots diagnosed with hypercholesterolemia to whom statins were 
prescribed and a control group with normal cholesterol, followed up for a minimum of 15 
months, from 1991 to 2002 (81). In this study, PSA declined an average of 42% over 5 years, 
and it raised the attention of the scientific community for the fact that this PSA decline could 
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represent further evidence of a preventive biologic effect of statins on the prostate and also 
for the fact that reduced PSA levels could lead to a delay on the referral for prostate biopsy, 
potentially causing missed or delayed prostate cancer diagnoses (81) (Figure 3). This delay 
causes a decrease risk of finding a localized tumour and an increased risk of finding advance 
tumours (79, 82). However, statins users are more likely to get PSA testing done, decreasing 
the time need to detect PSA levels high enough to trigger the diagnosis procedures, and this 
can be associated with an earlier detection of prostate cancer, leading to an increased risk of 
overall but a decreased risk of advanced prostate cancer (79, 82). 
 
Figure 3 – Association between statins’ use and localized and advanced stage prostate 
cancer (adapted from Mondul et al (82)). 
 
t0 – development of asymptomatic tumour at same stage and grade for all scenarios 
PSA – PSA screening test 
PSA  - PSA screening test when PSA concentration reached the level for referral for biopsy 
 
After this study other observational investigations provide biologic evidence that statins 
reduce PSA levels (38, 82-86), but they were not able to ascertain the extent to which statins 
use influences PSA nor if there is the need to lower PSA threshold in statins’ users. The 
main characteristics and results of these studies are summarized in Table 2.  
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Table 2 – Main characteristics of the studies assessing the relation between statins and Prostate Specific Antigen (PSA) levels. 
 
Author Year 
Sample 
Main findings Limitations 
Population Exclusion criteria 
Hamilton et 
al (83) 
2008 - computerized 
medical records at 
the Durham 
Veterans Affairs 
Medical Center of 
men who filled an 
outpatient 
prescription for a 
statin between 
January 1, 1990, 
and September 10, 
2006 and with at 
least one PSA 
value within two 
years before and at 
least one PSA 
value within one 
year after starting a 
statin (n=1214) 
- history/diagnosis of prostate 
cancer; 
- radical prostatectomy; 
- androgen deprivation therapy; 
- bilateral orchiectomy; 
- transurethral resection of the 
prostate; 
- simple open prostatectomy; 
- taking finasteride; 
- taking testosterone; 
- prostatitis; 
- pre-statin PSA undetectable or 
>10ng/mL 
- post-statin PSA undetectable; 
- not on statin at time of post-
statin PSA; 
-taking a non-statin lipid lowering 
agent within 3years before 
starting statin; 
- missing pre and post-statin LDL 
- median PSA 
decline 4.1% 
[IQR – 22.1% to 
+12.5%, 
P<0.001] per 
214 days; 
 
- for every 10% 
LDL cholesterol 
decline after 
statin initiation, 
PSA declined by 
1.64% 
- exclusion of men with PSA≥10ng/mL, 
does not allow to comment on the 
association between statin use and 
PSA decline in these subgroups; 
- unable to capture information on 
possible lifestyle changes initiated by 
men who started statins, changes that 
could possibly explain the relationship 
between statins and PSA change. 
- full demographic data not available for 
all statin users, thus unable to assess if 
men included and excluded from 
analysis differed;  
- medication prescribed outside the 
Veteran’s Administration system was 
not captured. Thus, men may have 
started medications (e.g., ﬁnasteride) 
that potentially accounted for the 
observed PSA declines.  
PSA – Prostate Specific Antigen 
IQR – Interquantile Range 
LDL – Low-density lipoprotein  
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Table 2 (Cont.) – Main characteristics of the studies assessing the relation between statins and Prostate Specific Antigen levels. 
 
Author Year 
Sample 
Main findings Limitations 
Population Exclusion criteria 
Mener et al 
(84) 
2009 -computerized medical 
records at the 
University of 
Rochester Medical 
Center to identify men 
who filled statin 
prescriptions between 
May 31st and 
September 30th, 2008 
and that underwent 
PSA testing within two 
years before and one 
year after starting 
statin therapy (n=962) 
- history of prostate 
cancer, prostatitis, 
prior prostatectomy, 
transurethral resection 
of prostate, bilateral 
orchiectomy or 
androgen deprivation 
therapy; 
- treatment with 
finasteride or 
androgen 
supplementation. 
- mean percent 
change: 8.04  
(-0.29ng/mL, 
95%CI: -0.29,-
0.22ng/mL) 
 
- mean follow-
up time: 
1.91years 
- not taking into account non-steroidal anti-
inflammatory medication use during the study 
period; 
- statin use was evaluated based upon 
prescription data, and not actual compliance, 
which may overestimate statin use among 
patients.  
- evaluation of patients with prescribed statins 
for <2 years and thus it may not allow for an 
observation of the peak reduction in serum PSA 
among patients. 
CI – Confidence Interval 
PSA – Prostate Specific Antigen 
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Table 2 (Cont.) – Main characteristics of the studies assessing the relation between statins and Prostate Specific Antigen levels. 
 
Author Year 
Sample 
Main findings Limitations 
Population Exclusion criteria 
Akduman et 
al (85) 
2010 men from a prostate 
cancer screening 
population who had not 
taken any form of statin 
compared with the ones 
who had the indication for 
current use of a statin 
(n=4903) 
N.A. Statins’ use shown 
significant 
association with 
lower PSA 
(P=0.008), after 
adjusting for age, 
BMI and race 
- unknown pre-statin serum PSA levels of 
patients receiving statin medication; does not 
allow to show the changes of serum PSA 
levels of these patients, and the relation of 
these changes to serum cholesterol changes. 
- unknown information regarding statin dose 
and compliance, and the effect of statin on 
LDL, HDL, and triglyceride.  
BMI – Body Mass Index 
HDL – High-density lipoprotein 
LDL – Low-density lipoprotein 
N.A. – Non-applicable 
PSA – Prostate Specific Antigen 
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Table 2 (Cont.) – Main characteristics of the studies assessing the relation between statins and Prostate Specific Antigen levels. 
 
Author Year 
Sample 
Main findings Limitations 
Population Exclusion criteria 
Murtola et al 
(86) 
2010 men participating in 
the Finnish Prostate 
Cancer Screening 
Trial from 1996 to 
2004 (n=23,320) 
- history of prostate 
cancer 
- age-adjusted HR of 
prostate cancer; 
0.62 (95%CI: 0.53-
0.72); 
- multivariable 
adjusted HR: 0.75 
(95%CI: 0.63-0.89) 
- age-adjusted mean 
PSA comparable 
between statins’ 
users and non-
users; 
- men aged 60-72 
who used statins 
had non-significantly 
lower PSA level 
compared to the 
ones not on statins 
- current statin users who had a history of 6 
months without medication purchases were 
reclassified to non-users until their next 
purchase, which may bias PSA level 
comparisons between the two groups towards 
the null; 
- 19.8% of men in the cohort used statin 
medications for less than 1 year, which may 
have been an insufficient amount of time to 
observe a substantial decrease in PSA. 
HR – Hazard ratio 
PSA – Prostate Specific Antigen 
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Table 2 (Cont.) – Main characteristics of the studies assessing the relation between statins and Prostate Specific Antigen levels. 
 
Author Year 
Sample 
Main findings Limitations 
Population Exclusion criteria 
Mondul et al 
(82) 
2010 male participants in 
the 2001–2002 and 
2003–2004 NHANES 
cycles, aged ≥40 years 
(n=2574) 
- history of prostate 
cancer; 
- prostate biopsy or 
infection 
-After multivariable adjustment for age, 
race/ethnicity, BMI and cigarette 
smoking status, men who reported 
currently using cholesterol-lowering 
drugs had a slightly lower PSA 
concentration (0.90ng/mL; 95%CI: 
0.85-0.96) compared with nonusers 
(0.95; 95%CI: 0.91-0.99), although the 
difference was not statistically 
significant, P=0.20. 
- limiting the analysis to men without 
co-morbidities, the association 
between statins and PSA was stronger 
and statistically significant 
- Cross-sectional nature 
that unable to longitudinally 
examine change in PSA 
concentration before and 
after statin use in the same 
man. 
BMI – Body Mass Index 
NHANES – National Health and Nutrition Examination Survey 
PSA – Prostate Specific Antigen 
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Table 2 (Cont.) – Main characteristics of the studies assessing the relation between statins and Prostate Specific Antigen levels. 
 
Author Year 
Sample 
Main findings Limitations 
Population Exclusion criteria 
Chang et al 
(38) 
2010 men ≥40 years old 
without prostate 
cancer from the 2003 
to 2004 and 2005 to 
2006 cycles of the 
NHANES survey 
-history of prostate 
cancer, prostatitis 
or recent prostate 
manipulation; 
- use of 5 ARI or 
other forms of 
hormone therapy; 
- incomplete 
medication, clinical 
or 
sociodemograhic 
data 
- inverse 
relationship 
between PSA 
levels and statin 
intake (P=0.01); 
- PSA levels after 1 
year of statins were 
3% lower, and after 
5years were 13% 
lower than those 
who weren’t taking 
medication 
- the relationship 
between statins 
and PSA is stable 
in men across a 
wide range of PSA 
values; 
- missing data in the NHANES dataset, may 
have been non-random, thus potentially 
resulting in non-responder bias; 
- cross-sectional nature of the study that 
precludes determination of a causal relationship 
between duration of medication use and 
differences in PSA levels; 
- unable to confirm the inverse relationship 
between PSA levels and NSAID, statin, and 
thiazide diuretic use substantially beyond 5 
years, given the lack of men using the 
medications for more than 5 years 
5-ARI – 5-α reductase inhibitors 
NHANES – National Health and Nutrition Examination Survey 
NSAID – Non-steroid anti-inflammatory drugs 
PSA – Prostate Specific Antigen 
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4. OBJECTIVES 
 
Prostate cancer is one of the main contributors to the high burden of cancer worldwide 
(6). It is the second most frequent cancer and the sixth cause of oncological death in men 
(1). Its incidence rates increased since the introduction of Prostate Specific Antigen (PSA) 
testing in the 1990s, but it have been stabilizing in the past decades, whilst mortality has 
been decreasing, mostly in developed countries (14). 
PSA is a specific prostate gland glycoprotein, secreted into the circulatory system in 
case of any modification in prostate physiology – Benign Prostate Hyperplasia, prostatitis, 
trauma, cancer (27). Although it is not specific for prostate cancer, there is unquestionable 
evidence that the higher the PSA value, the more likely is the existence of prostate cancer 
(27). 
The diagnosis of prostate cancer relies on the histopathologic confirmation of cancer in 
prostate biopsy (19). To refer for undergoing this invasive procedure, physicians must take 
into account digital rectal examination findings and serum PSA (19), interpreted according to 
patients’ age (42), body mass index (43) and medications used (38), namely statins (87). 
Statins are among the most prescribed anti-dyslipidemic drugs worldwide (58) and, in 
addition to the lipid lowering effects, the drugs belonging to this therapeutic group present 
anti-inflammatory, anti-invasive, tumour growth suppressing, apoptotic and angiogenesis 
inhibiting properties (64), potentially decreasing the risk of prostate cancer (79). Statins also 
contribute to a reduction in total PSA levels (81), reflecting the lowering of cholesterol levels, 
since it is a precursor in the synthesis of PSA, as well as due to their action on benign 
prostatic tissue (87). 
The impact of statins on serum PSA levels may lead to a decrease and a delay in 
prostate cancer detection when using the traditional cut-offs for reference to biopsy, and 
adjustment of the PSA threshold to maximize sensitivity and specificity may be needed 
among statins’ users. The present investigation has the following specific objectives, among 
patients referred to prostate biopsy: 
1) To quantify the direct, indirect and total effects of using statins on PSA levels; 
2) To assess the potential impact of the exposure to these drugs in the diagnostic 
accuracy of PSA.  
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5. MANUSCRIPT 
 
5.1. USE OF STATINS AND SERUM LEVELS OF PROSTATE SPECIFIC 
ANTIGEN 
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Abstract 
 
Background: Statins’ use has been associated with decrease risk of prostate cancer and 
with lower levels of serum total Prostate Specific Antigen (tPSA). 
Objective: To quantify the effect of statins’ use on tPSA levels in patients referred to prostate 
biopsy. To determinate if the exposure to statins must be considered to improve the prostate 
cancer diagnostic accuracy of tPSA. 
Design, setting and participants: We selected 551 patients referred to ultrasound guided 
trans-rectal prostate biopsy, with tPSA ≤10.0 ng/mL. Results of the prostatic pathology 
assessment (cancer versus non-cancer) were defined by biopsy. Information regarding 
statins’ use was obtained from patients’ clinical records. 
Outcome measure and statistical analysis: We used path analysis to quantify the effect of 
statins’ use on tPSA and Receiver Operating Characteristic curves to assess the global 
predictive accuracy of models including tPSA, age, body mass index, 5-α-reductase 
inhibitors, aspirin and statins’ use for distinguishing between prostate cancer and benign 
conditions. 
Results and limitations: We observed a negative total effect of statins on tPSA levels (β=-
0.283; 95% CI: -0.618, 0.051), mostly due to the direct effect (β=-0.243; 95% CI: -0.587, 
0.101) rather than the indirect effect (β=-0.040; 95%CI: -0.178, 0.097). There were no 
statistically significant differences between the area under the curve corresponding to the 
models with or without statins (P=0.554). The study is limited by its cross-sectional nature, 
and lack of information on the duration of treatment with statins. Results cannot be 
extrapolated to settings with a different risk of prostate cancer. 
Conclusions: In a consecutive sample of patients referred to prostate biopsy, statins’ use 
contributed to lower tPSA levels, but the clinical impact in these patients is low. 
Patients Summary: Among patients referred for prostatic biopsy, the current use of statins 
was associated with lower tPSA levels. However, the clinical impact in these patients is low. 
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Introduction 
 
The use of statins has been increasing over the last two decades [1, 2] due to the 
definition of successively lower cut-offs for cholesterol levels associated with high 
cardiovascular risk [3], the changes in the spectrum of statins’ indication – with 
recommendations for its use in both primary and secondary prevention of cardiovascular 
events [3] – and the intense marketing policies by pharmaceutical companies [4, 5]. 
Currently, statins are among the most prescribed drugs within countries of the Organization 
for the Economic Co-operation and Development (OECD), with an estimated average daily 
consumption of 85.3 Defined Daily Doses (DDDs) per 1000 people [6]. 
In addition to the lipid lowering properties of statins, these drugs have shown anti-
inflammatory, anti-invasive, tumour growth suppressing, apoptotic and angiogenesis 
inhibiting properties, potentially decreasing the risk of several cancers [7], including prostate 
cancer [7-9]. Statins may also contribute to a reduction in total Prostate Specific Antigen 
(tPSA) levels due to their action on benign prostatic tissue, in addition to the cholesterol 
lowering effects – a precursor in the synthesis of PSA [9]. Epidemiological evidence supports 
a lower risk of prostate cancer among statins users, and several observational studies have 
shown that non-cancer patients under treatment with statins, especially long therapy 
courses, present lower levels of serum tPSA [10-12]. 
The impact of statins on serum tPSA levels may lead to a decrease in prostate cancer 
detection when using the traditional cut-offs for reference to biopsy [11, 13], and adjustment 
of the tPSA threshold may be needed among statins’ users, to maximize sensitivity and 
specificity [14]. 
Therefore, we aimed to quantify the effect of using statins on tPSA levels, and to 
assess the potential impact of the exposure to these drugs in the diagnostic accuracy of 
tPSA, among patients referred to prostate biopsy. 
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Methods 
 
Between October 2009 and November 2012, we consecutively recruited patients, at 
the Department of Urology of Hospital de São João, Porto, Portugal, referred to ultrasound 
guided trans-rectal prostate biopsy on the basis of abnormal digital rectal examination (DRE) 
or tPSA ≥2.5ng/mL, and selected those with tPSA ≤10ng/mL. Before undergoing prostatic 
biopsy, weight and height were measured and a fasting blood sample was collected for 
assessment of tPSA and free PSA (fPSA). None of the patients had received hormone 
therapy, radiotherapy or chemotherapy previously. 
The results of the prostatic pathology assessment (cancer versus non-cancer) were 
defined by biopsy (12 to 14 biopsy cores). The participants with non-malignant disease in the 
first biopsy, but having a prostate cancer diagnosed within six months, were considered as 
cancer patients. 
Information gathered by the physicians regarding the patients’ prostatic volume, 
previous medical conditions and currently used medication was obtained from clinical 
records for a total of 551 patients. Data analysis was restricted to this group. 
Currently used medications were classified according to the Anatomical Therapeutic 
Chemical (ATC) classification system, from the 1st level – Anatomical main group – to 5th 
level – Chemical substance name) [15] – depending on the information available. Statins’ 
use was defined as the current treatment with any of the drugs belonging to ATC level 
C10AA (Hydroxy-methylglutaryl Coenzyme-A – HMG CoA – reductase inhibitors) including 
simvastatin (C10AA01), lovastatin (C10AA02), pravastatin (C10AA03), fluvastatin 
(C10AA04), atorvastatin (C10AA05), rosuvastatin (C10AA07) or pitavastatin (C10AA08). 
Statins were further classified as hydrophilic (pravastatin, rosuvastatin and pitavastatin ) or 
lipophilic (lovastatin, simvastatin, atorvastatin and fluvastatin). Data on specific dosage, 
duration of treatment or previously discontinued prescription medications were not 
systematically recorded and, therefore, not considered for analysis. 
The Mann-Whitney and the Chi-square tests were used to compare quantitative and 
categorical variables across groups, respectively. Statistically significance was considered 
when P<0.05. All reported P-values are two-sided. 
To quantify the effect of statins’ use in tPSA levels, we used path analysis to account 
for the relations between variables depicted in the Directed Acyclic Graph (DAG) [16] 
presented as Figure 1. Path analysis is an extension of regression analysis which allows for 
simultaneous estimation of the interrelations between variables in a set [17]. The variables 
were chosen assuming a causal relation between statins and tPSA levels and taking into 
account the potential confounders. The model depicted reflects the minimum needed to 
estimate the global effect of statins on tPSA levels, including the direct (corresponding to the 
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influence on PSA biology and metabolism), indirect (through the relation with the risk of 
prostate cancer, which, in turn, is related to tPSA levels) and total effect (the net result of 
direct and indirect effects). Models were fitted with Mplus software (Muthe´n and Muthe´n, 
Los Angeles, California); 95% confidence intervals were calculated by bootstrapping and 
models were considered to have a good fit when the estimated Root Mean Square Error of 
Approximation (RMSEA) was 0.05 [18]. 
We fitted logistic regression models, including cancer as the dependent variable and 
different combinations of tPSA, age, BMI, 5-α reductase inhibitors (5ARI), aspirin and statins’ 
use as independent variables, due to their impact on tPSA levels, and used the areas under 
the corresponding Receiver Operating Characteristic (ROC) curves to compare their 
predictive accuracy to distinguish between prostate cancer and benign prostatic conditions 
[19]. The analyses were performed using STATA®, version 11.2 (StataCorp LP, College 
Station, TX, USA). 
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Results 
There were a total of 149 statins’ users: 42.3% used simvastatin, 1.3% lovastatin, 
18.1% pravastatin, 4.7% fluvastatin, 17.4% atorvastatin, 12.8% rosuvastatin and 0.7% 
pitavastatin. No significant differences were found between statins’ users and non-users, 
except for f/t PSA ratio among cancer patients, despite the tendency for statins’ users to be 
older and to have lower tPSA and fPSA levels, and f/t PSA (Table1). 
Figure 1 presents the relation between the variables tested to assess the plausibility 
of an effect of statins’ use on tPSA levels, using path analysis; the overall fit of the model 
was good (RMSEA=0.00). We observed a negative total effect of statins on tPSA levels (β=-
0.283; 95% CI: -0.618, 0.051), mostly due to a direct (β= -0.243; 95% CI: -0.587, 0.101) 
rather than an indirect effect (β=-0.040, 95%CI: -0.178, 0.097). When considering specifically 
the use of lipophilic or hydrophilic statins, the former were more strongly associated with 
tPSA levels (total effect: β=-0.246; 95%CI: -0.610, 0.118 vs. β=-0.069; 95%CI: -0.465, 
0.328). 
Figure 2 depicts the ROC curves that reflect the global predictive accuracy of models 
including tPSA, age, BMI, 5ARI, aspirin and statins’ use for distinguishing between prostate 
cancer and prostate benign conditions. There were no statistically significant differences 
between the area under the curve (AUC) corresponding to the models with or without statins 
(P=0.554). Furthermore, there was no meaningful or statistically significant difference in the 
predicted probability of prostate cancer detection among statins users (24%; 95%CI: 17-31) 
and non-users (27%; 95%CI: 21-32) when setting the tPSA value to 4ng/mL and considering 
the mean values of the remaining variables included in the model. 
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Discussion 
 
In a group of patients referred to prostate biopsy there was a negative non-significant 
effect of statins on tPSA levels, especially for lipophilic statins, and mainly due to a direct 
action on PSA synthesis and metabolism. However, taking into account the current use of 
statins did not affect meaningfully tPSA predictive accuracy for prostate cancer diagnosis. 
Furthermore, no important difference in the predictive value of PSA testing is to be expected 
according to statins use, since the probability of prostate cancer was similar among users 
and non-users.  
Previous studies that evaluated the relationship between statins and tPSA levels 
found lower levels of tPSA among statins users [10-13, 20-22]; the relative difference in PSA 
levels between statins users and non-users was -3% and -13% after one and five years of 
therapy with statins, respectively, in a sample from participants in the National Health and 
Nutrition Examination Survey (NHANES) [13, 20]. However, methodological differences 
preclude direct comparison between our results and the ones from most studies conducted 
before. 
Concerning the relationship between statins and cancer, we observed a non-
significantly lower risk of prostate cancer, which is also in agreement with other studies that 
used a similar setting – men referred to prostate biopsy. In these studies, the risk ratios (RR) 
for prostate cancer diagnosis were 0.92 (95% CI: 0.85-0.99) [23] and 0.95 (95% CI: 0.73-
1.24) [24] when adjusting for different confounders. Regarding the other relations depicted, 
the magnitudes of effects are in accordance with the available evidence with an exception for 
the association between aspirin use and tPSA levels [25, 26], since previous observational 
studies showed lower tPSA levels among aspirin users [13]. Regarding different statins 
grouped according to their solubility, our results agree with the hypotheses that lipophilic 
statins present greater intracellular access and therefore may be most effective in lowering 
PSA levels [7, 27]. 
Our study adds to previous research on this topic a comprehensive assessment of 
the impact of use of statins in prostate cancer; we quantified the statins direct (statins → 
tPSA) and indirect (statins → cancer → tPSA) effect – through path analysis – and assessed 
the impact of decreased tPSA levels among statins’ users in the prediction of prostate cancer 
– through ROC curve analysis. Nevertheless, some limitations need to be discussed. The 
absence of information from the patient’s clinical records regarding the duration of treatment 
with statins, since it is one of the main determinants for statins anti-carcinogenic activity [10, 
13] contributes to an underestimation of the association between statins and prostate cancer 
and may help to explain why we observed a larger contribution from the direct effect on tPSA 
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levels. The cross-sectional nature of our analyses does not allow us to confirm the 
precedence of the exposure to statins over the observed tPSA levels. Although it is unlikely 
that there is a causal relation between low tPSA and the use of statins, the absence of 
information regarding access to health care services could have resulted in an 
overestimation of the direct effects of statins’ on tPSA levels [12, 26]. People who have a 
better access to health care are more likely to be prescribed a statin, possibly leading to 
lower tPSA levels, as well as to undergo tPSA testing more frequently and to be diagnosed 
with a prostate cancer on the basis of lower tPSA values. This probably had little impact in 
the internal validity of our findings, since all participants were referred for prostatic biopsy 
and a relatively high homogeneity in the access to health care may be expected among 
them. However, our results cannot be extrapolated to the general population or clinical 
settings with different risk of prostate cancer. 
In conclusion, in a consecutive sample of patients referred to prostate biopsy we 
observed that statins’ use was associated with lower tPSA levels, but the clinical impact of 
this relation is low. Further investigation is needed to obtain more robust and generalizable 
estimates of the relation between the use of statins and tPSA levels. 
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Table 1 – Characteristics of the patients according to prostate biopsy diagnosis and statins’ use. 
  Non cancer (n=362)  Cancer (n=189)  
  Non user (n=269) User (n=93)  Non user (n=144) User (n=45)  
 N* Median (P25-P75) δ p-value† Median (P25-P75) δ p-value† 
Age (years) 551 65 (60-70) 66 (62-71) 0.057 66 (62-72) 68(62-74) 0.231 
tPSA (ng/mL) 551 5.45 (4.00-7.35) 5.30 (3.54-6.60) 0.323 6.83 (5.15-8.30) 6.30 (5.06-7.04) 0.242 
fPSA (ng/mL) 542 0.89 (0.59-1.39) 0.85 (0.56-1.28) 0.328 0.86 (0.59-1.26) 0.69 (0.49-1-03) 0.029 
f/t PSA 542 0.18 (0.14-0.24) 0.17 (0.13-0.24) 0.764 0.14 (0.09-0.20) 0.11 (0.08-0.17) 0.182 
Abnormal DRE [n (%)] 159 61 (25.7) 18 (23.1) 0.638 56 (43.8) 24 (60) 0.056 
Prostatic volume (mL) 472 59.5 (44-84) 60.0 (44-84) 0.996 45 (35-60) 48(40-60) 0.555 
BMI (kg/m2) 551 26.4 (24.1-28.5) 26.6 (24.6-28.5) 0.461 26.5 (24.2-29.4) 26.0 (23.9-28.7) 0.545 
 
P25-P75 – percentile 25-percentile 75 
BMI – Body Mass Index 
tPSA – total Prostate Specific Antigen 
fPSA – free Prostate Specific Antigen 
f/t PSA – free/total Prostate Specific Antigen ratio 
 
* the number of participants may be lower due to missing data 
δ as appropriate 
† p-value for the comparison of statins’ users vs non users 
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Figure 1 – Directed Acyclic Graph (DAG) representing estimates of direct (solid thick 
line) and indirect (solid dashed lines) effects of Statins on total Prostate Specific 
Antigen (tPSA) levels, calculated by path analysis*. 
 
 
Direct effect (Statins → tPSA): β1= -0.243 (-0.587; 0.101)  
Indirect effect (Statins → Cancer → tPSA) β2 x β3 = -0.040 (-0.178; 0.097)  
Total effect: β1+ (β2 x β3)= -0.283 (-0.618; 0.051) 
 
* The regression coefficients (β) and 95% confidence intervals (95% CI) were obtained 
using linear (presented in italic) or logistic (bold) regression models, as appropriate. 
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Figure 2 – Receiver operating characteristic (ROC) curves for global predictive 
accuracy of different combinations of total PSA (tPSA), age, Body Mass Index (BMI), 
aspirin, 5-α reductase inhibitors (5ARI) and statins’ use for prostate cancer diagnosis 
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6. CONCLUSIONS 
 
With this study, we were able to quantify the direct (statins → tPSA) and 
indirect (statins → cancer → tPSA) effects of statins using path analysis, and 
assessed the impact of decreased tPSA levels among statins’ users in the 
prediction of prostate cancer by comparing the Receiver Operating 
Characteristic curves, in a population of patients referred to prostate biopsy. 
We concluded that the current use of statins, especially lipophilic statins, 
was associated with lower tPSA levels, mainly due to a direct action on PSA 
synthesis and metabolism, though this had little impact on the predictive value 
of PSA testing in this setting. 
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